Therapeutic Advances in IgA Nephropathy: Atacicept and B-Cell Modulation

Atacicept for the treatment of IgAN has entered the FDA accelerated Biologics License Application pathway after Phase III ORIGIN 3 data showed a 46% reduction in proteinuria versus placebo.

The agent represents a potential disease-modifying option beyond supportive care and RAAS blockade. It dual-targets BAFF and APRIL to modulate B-cell activity, reduce pathogenic IgA production, and impair plasma-cell survival.

Across the ORIGIN program, the reported safety profile was similar to placebo. Nonetheless, B-cell modulation carries infection risk and other class-associated concerns.